|
Cannabidivarin (CBDV) is a non-psychoactive cannabinoid found in ''Cannabis''. It is a homolog of cannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH2 units). Plants with relatively high levels of CBDV have been reported in feral populations of ''C. indica'' ( = ''C. sativa'' ssp. ''indica'' var. ''kafiristanica'') from northwest India, and in hashish from Nepal. CBDV has anticonvulsant effects. Similarly to CBD, it has 7 double bond isomers and 30 stereoisomers (see: Cannabidiol#Double bond isomers and their stereoisomers). It is not scheduled by Convention on Psychotropic Substances. It is being actively developed by GW Pharmaceuticals〔http://www.gwpharm.com/therapeutic-areas.aspx〕 (as GWP42006)because of a demonstrated neurochemical pathway for previously-observed anti-epileptic and anti-convulsive action. GW has begun a phase 2 trial for adult epilepsy, and is to begin trials of this CBDV product in children in 2016 in Australia. == See also == * Cannabinoids * Cannabis * Medical marijuana 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Cannabidivarin」の詳細全文を読む スポンサード リンク
|